Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended September 30, 2021						Nine Months Ended September 30, 2021
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	217	$	217	$	—	$	656	$	656	$	—
License Fee – Over time	62		—		62		179		—		179
Total Drug Products	279		217		62		835		656		179
Concentrate Products
Product Sales – Point-in-time	15,224		13,541		1,683		44,308		39,768		4,540
License Fee – Over time	485		485		—		1,456		1,456		—
Total Concentrate Products	15,709		14,026		1,683		45,764		41,224		4,540
Net Revenue	$	15,988	$	14,243	$	1,745	$	46,599	$	41,880	$	4,719

In thousands of U.S. dollars ($)	Three Months Ended September 30, 2020						Nine Months Ended September 30, 2020
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	228	$	228	$	—	$	609	$	609	$	—
License Fee – Over time	56		—		56		167		—		167
Total Drug Products	284		228		56		776		609		167
Concentrate Products
Product Sales – Point-in-time	14,506		13,470		1,036		44,786		40,295		4,491
License Fee – Over time	490		490		—		1,471		1,471		—
Total Concentrate Products	14,996		13,960		1,036		46,257		41,766		4,491
Net Revenue	$	15,280	$	14,188	$	1,092	$	47,033	$	42,375	$	4,658

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	September 30, 2021		December 31, 2020
Receivables, which are included in "Trade and other receivables"	$	6,036	$	4,171
Contract liabilities	$	8,705	$	10,190